Premium
The implanted glucose monitoring system Eversense: An alternative for diabetes patients with isobornyl acrylate allergy
Author(s) -
Oppel Eva,
Kamann Stefanie,
Heinemann Lutz,
Reichl FranzXaver,
Högg Christof
Publication year - 2020
Publication title -
contact dermatitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.524
H-Index - 96
eISSN - 1600-0536
pISSN - 0105-1873
DOI - 10.1111/cod.13392
Subject(s) - medicine , diabetes mellitus , allergy , adhesive , allergic contact dermatitis , irritation , acrylate , skin irritation , dermatology , continuous glucose monitoring , surgery , biomedical engineering , type 1 diabetes , chemistry , immunology , organic chemistry , endocrinology , copolymer , polymer , layer (electronics)
Abstract Background Some patients with diabetes develop skin reactions when using systems for continuous glucose monitoring (CGM) or insulin pumps. Regular usage and long wearing periods lead not only to skin irritation, but also to allergic contact dermatitis. It has been shown that allergens such as isobornyl acrylate (IBOA) are present in the plastic housing and also in the adhesives of medical devices used for diabetes treatment. Objectives To evaluate the IBOA content of all parts of a newly introduced, implanted CGM system (Eversense) to check whether this can be an alternative for IBOA‐sensitized patients. Methods The IBOA content of the implanted sensor itself (n = 3), the transmitter (n = 3), and two different types of adhesive (white adhesive [n = 4] and clear adhesive [n = 4]) was measured by gas chromatography/mass spectrometry. Results No IBOA was found in any part of this CGM system. Conclusions Patients with an IBOA allergy may be able to use this implanted CGM system.